TapImmune Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative vaccine technologies for the treatment of various cancers and infectious diseases. The Company’s peptide or nucleic acid-based vaccine compositions comprise one of multiple naturally processed epitopes (NPEs) which recognize and bind to antigen-presenting cells in the immune system. Our approach is designed to comprehensively stimulate a patients’ killer T-cells and helper T-cells, and restore or further supplement antigen presentation. We select antigen combinations that can lead to the treatment of wider patient populations in numerous indications and in varied therapeutic areas of cancer.
TapImmune’s comprehensive approach to T-cell vaccines addresses the deficiencies seen in earlier approaches so that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities and newly immerging immunotherapy approaches.
We are currently conducting preclinical and clinical trials in breast and ovarian cancer to explore the promising commercial potential of our comprehensive approach to immunotherapy. In ovarian cancer the development and commercial pathway has been facilitated by the granting of Orphan Drug Status and Fast Track Designation by the FDA. In addition, the USPTO recently granted patent claims to our internally-developed PolyStart technology, slated to become the next generation of vaccine technologies. This all-encompassing approach makes TapImmune a leading innovator and world class immuno-oncology company.